25
Tue, Apr
9 New Articles

Takeda Pharmaceutical Company Limited announced that the European Commission has granted an expanded indication for surgical patch TachoSil (human thrombin/human fibrogen) for use in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery. Dura mater is the outermost and most fibrous of the three membranes covering the brain and spinal cord.

Designation based on results of Phase 3 study, CheckMate -141, in which Opdivo met its primary endpoint of overall survival, versus three standard of care options in this patient population.

Designation signals the urgent need for new treatment approaches in recurrent or metastatic squamous cell carcinoma of the head and neck after platinum based therapy

Mallinckrodt plc a leading global specialty biopharmaceutical company announced the results from a retrospective analysis of health economic data on the use of OFIRMEV (acetaminophen) injection as part of multimodal analgesia (MMA) for the treatment of acute postoperative pain following elective orthopedic surgery.

Total spending on medicines in the U.S. reached $310 billion in 2015 on an estimated net price basis, up 8.5 percent from the previous year, according to a new report issued today by the IMS Institute for Healthcare Informatics. The surge of new medicines remained strong last year and demand for recently launched brands maintained historically high levels. The savings from branded medicines facing generic competition were relatively low in 2015, and the impact of price increases on brands was limited due to higher rebates and price concessions from manufacturers. Specialty drug spending reached $121 billion on a net price basis, up more than 15 percent from 2014.

AbbVie and CytomX Therapeutics, Inc announced that they have entered into a collaboration to co-develop and co-commercialize Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). CD71 is highly expressed in a number of solid and hematologic cancers and has attractive molecular properties for efficient delivery of cytotoxic payloads to tumor cells. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Teva Pharmaceutical Industries Ltd., announced new data from the Phase III placebo-controlled and randomized First Time Use of SD-809 in HuntingtonDisease (First-HD) study evaluating the efficacy, safety and tolerability of SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). The data will be featured during two Platform Sessions at the 68thAmerican Academy of Neurology (AAN) meeting in Vancouver, B.C.

Cerebral cavernous malformations (CCMs) are clusters of dilated, thin-walled blood vessels in the brain that can cause stroke and seizures, yet exactly how they form is somewhat of a mystery. Now, a team from the Perelman School of Medicine at the University of Pennsylvania has discovered the molecular mechanism that underlies this common cerebrovascular disease. They published their results this week online ahead of print in Nature.

More Articles ...